The Experts below are selected from a list of 834 Experts worldwide ranked by ideXlab platform

Ehab Y Hanna - One of the best experts on this subject based on the ideXlab platform.

  • Neuroendocrine Carcinoma and Sinonasal Undifferentiated Carcinoma.
    Advances in oto-rhino-laryngology, 2020
    Co-Authors: Ahmed S. Abdelmeguid, Diana Bell, Ehab Y Hanna
    Abstract:

    Sinonasal malignancies are uncommon, representing 1% of all neoplasms. A wide spectrum of malignant neoplasms arise from the Sinonasal and skull base regions; the majority of these tumors are poorly or Undifferentiated tumors manifesting overlapping features that result in diagnostic challenges. Sinonasal neuroendocrine Carcinoma (SNEC) and Sinonasal Undifferentiated Carcinoma (SNUC) are types of Sinonasal neuroendocrine tumor, together with olfactory neuroblastoma. They share overlapping clinical, radiological, and histopathological features, albeit with variability in behavior and prognosis between each other. The literature is at variance regarding the appropriate management strategy of these tumors due to their rarity and difficulty in establishing the correct diagnosis. In recent years progress has been made in the diagnostic techniques and treatment strategies implemented for these tumors. Here we provide a comprehensive review of the recent literature, focusing on the recent advances in histopathological and ancillary diagnosis, and different treatment options for SNEC and SNUC.

  • Management of olfactory neuroblastoma, neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma involving the skullbase
    Journal of Neuro-Oncology, 2020
    Co-Authors: Gautam U. Mehta, Shirley Y. Su, Ehab Y Hanna, Shaan M. Raza, Franco Demonte
    Abstract:

    Introduction Sinonasal tumors that harbor neuroendocrine histologic features include olfactory neuroblastoma (previously known as esthesioneuroblastoma), Sinonasal neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma. These tumors represent a diverse spectrum of clinical behavior and as such require histology-specific management. Herein, we review the management of these Sinonasal tumors with neuroendocrine features and discuss fundamentals of multi-modality care for each histology. An emphasis is placed on olfactory neuroblastomas, given their relative frequency and skullbase origin. Methods A comprehensive literature review on contemporary management of olfactory neuroblastoma, Sinonasal neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma was performed. Results Management of Sinonasal tumors with neuroendocrine features can include surgical resection, radiation therapy, and/or chemotherapy. Due to their site of origin, these tumors can frequently involve the skullbase, which can require site-specific care. The optimal treatment modalities and the sequence in which they are performed are largely dependent on histology. In most cases, olfactory neuroblastoma is best managed with surgical resection followed by radiation therapy. Sinonasal neuroendocrine Carcinomas represent a variety of histologic phenotypes (carcinoid, atypical carcinoid, small cell, and large cell), which determine the optimal treatment modality. Finally, Sinonasal Undifferentiated Carcinoma is likely best managed by induction chemotherapy with subsequent therapy dictated by the initial response. Conclusions A team approach to multi-modality care is essential in the treatment of olfactory neuroblastoma, Sinonasal neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma. Early biopsy, histologic diagnosis, and comprehensive imaging are critical to determining the appropriate management paradigm.

  • Management of olfactory neuroblastoma, neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma involving the skullbase
    Journal of Neuro-Oncology, 2020
    Co-Authors: Gautam U. Mehta, Ehab Y Hanna, Shaan M. Raza, Franco Demonte
    Abstract:

    Introduction Sinonasal tumors that harbor neuroendocrine histologic features include olfactory neuroblastoma (previously known as esthesioneuroblastoma), Sinonasal neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma. These tumors represent a diverse spectrum of clinical behavior and as such require histology-specific management. Herein, we review the management of these Sinonasal tumors with neuroendocrine features and discuss fundamentals of multi-modality care for each histology. An emphasis is placed on olfactory neuroblastomas, given their relative frequency and skullbase origin. Methods A comprehensive literature review on contemporary management of olfactory neuroblastoma, Sinonasal neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma was performed. Results Management of Sinonasal tumors with neuroendocrine features can include surgical resection, radiation therapy, and/or chemotherapy. Due to their site of origin, these tumors can frequently involve the skullbase, which can require site-specific care. The optimal treatment modalities and the sequence in which they are performed are largely dependent on histology. In most cases, olfactory neuroblastoma is best managed with surgical resection followed by radiation therapy. Sinonasal neuroendocrine Carcinomas represent a variety of histologic phenotypes (carcinoid, atypical carcinoid, small cell, and large cell), which determine the optimal treatment modality. Finally, Sinonasal Undifferentiated Carcinoma is likely best managed by induction chemotherapy with subsequent therapy dictated by the initial response. Conclusions A team approach to multi-modality care is essential in the treatment of olfactory neuroblastoma, Sinonasal neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma. Early biopsy, histologic diagnosis, and comprehensive imaging are critical to determining the appropriate management paradigm.

  • Management of olfactory neuroblastoma, neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma involving the skullbase.
    Journal of neuro-oncology, 2020
    Co-Authors: Gautam U. Mehta, Ehab Y Hanna, Shaan M. Raza, Franco Demonte
    Abstract:

    Sinonasal tumors that harbor neuroendocrine histologic features include olfactory neuroblastoma (previously known as esthesioneuroblastoma), Sinonasal neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma. These tumors represent a diverse spectrum of clinical behavior and as such require histology-specific management. Herein, we review the management of these Sinonasal tumors with neuroendocrine features and discuss fundamentals of multi-modality care for each histology. An emphasis is placed on olfactory neuroblastomas, given their relative frequency and skullbase origin. A comprehensive literature review on contemporary management of olfactory neuroblastoma, Sinonasal neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma was performed. Management of Sinonasal tumors with neuroendocrine features can include surgical resection, radiation therapy, and/or chemotherapy. Due to their site of origin, these tumors can frequently involve the skullbase, which can require site-specific care. The optimal treatment modalities and the sequence in which they are performed are largely dependent on histology. In most cases, olfactory neuroblastoma is best managed with surgical resection followed by radiation therapy. Sinonasal neuroendocrine Carcinomas represent a variety of histologic phenotypes (carcinoid, atypical carcinoid, small cell, and large cell), which determine the optimal treatment modality. Finally, Sinonasal Undifferentiated Carcinoma is likely best managed by induction chemotherapy with subsequent therapy dictated by the initial response. A team approach to multi-modality care is essential in the treatment of olfactory neuroblastoma, Sinonasal neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma. Early biopsy, histologic diagnosis, and comprehensive imaging are critical to determining the appropriate management paradigm.

  • Identification of markers predictive for response to induction chemotherapy in patients with Sinonasal Undifferentiated Carcinoma.
    Oral oncology, 2019
    Co-Authors: Yoko Takahashi, Diana Bell, Jeffrey N. Myers, Ahmed S. Abdelmeguid, Dianna B. Roberts, Frederico O. Gleber-netto, Tong Xin Xie, Curtis R. Pickering, Ehab Y Hanna
    Abstract:

    Abstract Objectives Sinonasal Undifferentiated Carcinoma (SNUC) is a rare, highly aggressive cancer. Despite aggressive multimodal therapy, its prognosis remains poor. Because of its locally advanced nature and high propensity for distant metastasis, we frequently use induction chemotherapy before definitive therapy in patients with SNUC. However, about 30% of patients do not respond to induction chemotherapy, and lack of response is associated with a poor survival rate. Therefore, in this study, we performed gene expression analysis of SNUC samples to identify prognostic markers for induction chemotherapy response. Materials and methods Formalin-fixed, paraffin-embedded SNUC tumor samples from previously untreated patients harvested before induction chemotherapy were used. Gene expression was performed using an oncology gene expression panel. Results We identified 34 differentially expressed genes that distinguish the responders from the non-responders. Pathway analysis using these genes revealed alteration of multiple pathways between the two groups. Of these 34 genes, 24 distinguished between these two groups. Additionally, 16 gene pairs were associated with response to induction therapy. Conclusion We identified genes predictive of SNUC response to induction chemotherapy and pathways potentially associated with treatment outcome. This is the first report of identification of predictive biomarkers for response of SNUC to induction chemotherapy, and it may help us develop therapeutic strategies to improve the treatment outcomes of non-responders.

Raewyn G. Campbell - One of the best experts on this subject based on the ideXlab platform.

  • role of 18 f fdg pet ct differentiating olfactory neuroblastoma from Sinonasal Undifferentiated Carcinoma
    Laryngoscope, 2017
    Co-Authors: Ahmad Elkhatib, Daniel M. Prevedello, Ricardo L. Carrau, Liuba Soldatova, Ralph Abi Hachem, Leo F. Ditzel, Raewyn Campbell, Luciano M. Prevedello, Leo Ditzel F S Filho, Raewyn G. Campbell
    Abstract:

    Objectives The purpose of this study is to demonstrate the potential contribution of positron emission tomography (PET)/computed tomography (CT) to help differentiate olfactory neuroblastoma (ONB) from Sinonasal Undifferentiated Carcinoma (SNUC). Methods Following approval by the institutional review board at the Wexner Medical Center at the Ohio State University, Columbus, Ohio, a pilot study with retrospective review of patients with biopsy-proven diagnosis of ONB s and SNUC s was conducted. Staging PET/CT scans were reviewed to document the maximum standardized uptake value (SUVmax). A statistical comparison of SUVmax was performed. Results We identified 13 patients (7 with ONBs and 6 with SNUCs) with mean age 60.2 years who had undergone staging F-18 fluorodeoxyglucose (18F-FDG) PET/CT of the primary tumor at the time of their diagnosis. Mean SUVmax was found to be five-fold higher in SNUC patients (35.63, range 10.8–77.9) than in ONB patients (7.24, range 4.6–10.7) (P ≤ 0.00169). Conclusion Maximum standardized uptake value of 18F-FDG PET/CT can be used to initially discriminate between ONB and SNUC. This finding may prove helpful to guide diagnostic and treatment planning when the histopathologic diagnosis is inconclusive. Level of Evidence 4. Laryngoscope, 2016

  • Role of (18) F-FDG PET/CT differentiating olfactory neuroblastoma from Sinonasal Undifferentiated Carcinoma.
    The Laryngoscope, 2016
    Co-Authors: Ahmad Elkhatib, Daniel M. Prevedello, Ricardo L. Carrau, Liuba Soldatova, Ralph Abi Hachem, Leo F. Ditzel, Raewyn Campbell, Luciano M. Prevedello, Leo F. S. Ditzel Filho, Raewyn G. Campbell
    Abstract:

    Objectives The purpose of this study is to demonstrate the potential contribution of positron emission tomography (PET)/computed tomography (CT) to help differentiate olfactory neuroblastoma (ONB) from Sinonasal Undifferentiated Carcinoma (SNUC). Methods Following approval by the institutional review board at the Wexner Medical Center at the Ohio State University, Columbus, Ohio, a pilot study with retrospective review of patients with biopsy-proven diagnosis of ONB s and SNUC s was conducted. Staging PET/CT scans were reviewed to document the maximum standardized uptake value (SUVmax). A statistical comparison of SUVmax was performed. Results We identified 13 patients (7 with ONBs and 6 with SNUCs) with mean age 60.2 years who had undergone staging F-18 fluorodeoxyglucose (18F-FDG) PET/CT of the primary tumor at the time of their diagnosis. Mean SUVmax was found to be five-fold higher in SNUC patients (35.63, range 10.8–77.9) than in ONB patients (7.24, range 4.6–10.7) (P ≤ 0.00169). Conclusion Maximum standardized uptake value of 18F-FDG PET/CT can be used to initially discriminate between ONB and SNUC. This finding may prove helpful to guide diagnostic and treatment planning when the histopathologic diagnosis is inconclusive. Level of Evidence 4. Laryngoscope, 2016

Diana Bell - One of the best experts on this subject based on the ideXlab platform.

  • Neuroendocrine Carcinoma and Sinonasal Undifferentiated Carcinoma.
    Advances in oto-rhino-laryngology, 2020
    Co-Authors: Ahmed S. Abdelmeguid, Diana Bell, Ehab Y Hanna
    Abstract:

    Sinonasal malignancies are uncommon, representing 1% of all neoplasms. A wide spectrum of malignant neoplasms arise from the Sinonasal and skull base regions; the majority of these tumors are poorly or Undifferentiated tumors manifesting overlapping features that result in diagnostic challenges. Sinonasal neuroendocrine Carcinoma (SNEC) and Sinonasal Undifferentiated Carcinoma (SNUC) are types of Sinonasal neuroendocrine tumor, together with olfactory neuroblastoma. They share overlapping clinical, radiological, and histopathological features, albeit with variability in behavior and prognosis between each other. The literature is at variance regarding the appropriate management strategy of these tumors due to their rarity and difficulty in establishing the correct diagnosis. In recent years progress has been made in the diagnostic techniques and treatment strategies implemented for these tumors. Here we provide a comprehensive review of the recent literature, focusing on the recent advances in histopathological and ancillary diagnosis, and different treatment options for SNEC and SNUC.

  • Identification of markers predictive for response to induction chemotherapy in patients with Sinonasal Undifferentiated Carcinoma.
    Oral oncology, 2019
    Co-Authors: Yoko Takahashi, Diana Bell, Jeffrey N. Myers, Ahmed S. Abdelmeguid, Dianna B. Roberts, Frederico O. Gleber-netto, Tong Xin Xie, Curtis R. Pickering, Ehab Y Hanna
    Abstract:

    Abstract Objectives Sinonasal Undifferentiated Carcinoma (SNUC) is a rare, highly aggressive cancer. Despite aggressive multimodal therapy, its prognosis remains poor. Because of its locally advanced nature and high propensity for distant metastasis, we frequently use induction chemotherapy before definitive therapy in patients with SNUC. However, about 30% of patients do not respond to induction chemotherapy, and lack of response is associated with a poor survival rate. Therefore, in this study, we performed gene expression analysis of SNUC samples to identify prognostic markers for induction chemotherapy response. Materials and methods Formalin-fixed, paraffin-embedded SNUC tumor samples from previously untreated patients harvested before induction chemotherapy were used. Gene expression was performed using an oncology gene expression panel. Results We identified 34 differentially expressed genes that distinguish the responders from the non-responders. Pathway analysis using these genes revealed alteration of multiple pathways between the two groups. Of these 34 genes, 24 distinguished between these two groups. Additionally, 16 gene pairs were associated with response to induction therapy. Conclusion We identified genes predictive of SNUC response to induction chemotherapy and pathways potentially associated with treatment outcome. This is the first report of identification of predictive biomarkers for response of SNUC to induction chemotherapy, and it may help us develop therapeutic strategies to improve the treatment outcomes of non-responders.

  • Identification of novel diagnostic markers for Sinonasal Undifferentiated Carcinoma.
    Head & neck, 2019
    Co-Authors: Yoko Takahashi, Diana Bell, Jeffrey N. Myers, Ahmed S. Abdelmeguid, Dianna B. Roberts, Frederico O. Gleber-netto, Tong Xin Xie, Curtis R. Pickering, Ehab Y Hanna
    Abstract:

    Background Sinonasal Undifferentiated Carcinoma (SNUC) is a rare, highly aggressive cancer. It is often difficult to determine whether SNUC is a distinct pathologic entity with poorly differentiated neuroendocrine features or it represents an Undifferentiated tumor of squamous lineage. Also, reliable histopathologic markers that distinguish SNUC from poorly differentiated Sinonasal squamous cell Carcinoma (SNSCC) are lacking. Therefore, identification of new diagnostic molecular markers for SNUC is needed. Methods Treatment-naive tumor specimens obtained from 15 SNUC and 6 SNSCC patients were used. Gene expression analysis was performed using an oncology panel. Results An unsupervised cluster analysis divided the patients into the one with only SNUCs and the one with mainly SNSCCs. Of 132 differentially expressed genes, 7 genes completely distinguished SNUCs from SNSCCs. SNUCs were enriched in sets of genes related to DNA repair, synthesis/replication, and cell division. Conclusions Our study identified new diagnostic markers and potential therapeutic targets for SNUC.

  • Sinonasal Undifferentiated Carcinoma.
    Current oncology reports, 2019
    Co-Authors: Ahmed S. Abdelmeguid, Diana Bell, Ehab Y Hanna
    Abstract:

    To provide a comprehensive review of the literature highlighting the recent advances in the diagnosis and management of Sinonasal Undifferentiated Carcinoma (SNUC) SNUC usually presents at advanced stage and the prognosis is usually poor with high rates of locoregional recurrence and tendency to metastasize. Special attention should be made in differentiating SNUC from other Sinonasal malignancies in order to guide the appropriate treatment accordingly. Multimodality treatment is usually recommended for treating SNUC. The use of neoadjuvant chemotherapy may be associated with improved outcome and can be used to guide the subsequent treatment selection. Despite the recent advances in chemotherapeutic agents, radiation techniques, and surgical approaches, the prognosis and survival outcomes of SNUC remain poor. The addition of induction chemotherapy to the treatment approach followed by definitive local therapy needs to be further studied as it might improve the outcome.

  • Sinonasal Undifferentiated Carcinoma
    Current Oncology Reports, 2019
    Co-Authors: Ahmed S. Abdelmeguid, Diana Bell, Ehab Y Hanna
    Abstract:

    Purpose of Review To provide a comprehensive review of the literature highlighting the recent advances in the diagnosis and management of Sinonasal Undifferentiated Carcinoma (SNUC) Recent Findings SNUC usually presents at advanced stage and the prognosis is usually poor with high rates of locoregional recurrence and tendency to metastasize. Special attention should be made in differentiating SNUC from other Sinonasal malignancies in order to guide the appropriate treatment accordingly. Multimodality treatment is usually recommended for treating SNUC. The use of neoadjuvant chemotherapy may be associated with improved outcome and can be used to guide the subsequent treatment selection. Summary Despite the recent advances in chemotherapeutic agents, radiation techniques, and surgical approaches, the prognosis and survival outcomes of SNUC remain poor. The addition of induction chemotherapy to the treatment approach followed by definitive local therapy needs to be further studied as it might improve the outcome.

Ahmed S. Abdelmeguid - One of the best experts on this subject based on the ideXlab platform.

  • Neuroendocrine Carcinoma and Sinonasal Undifferentiated Carcinoma.
    Advances in oto-rhino-laryngology, 2020
    Co-Authors: Ahmed S. Abdelmeguid, Diana Bell, Ehab Y Hanna
    Abstract:

    Sinonasal malignancies are uncommon, representing 1% of all neoplasms. A wide spectrum of malignant neoplasms arise from the Sinonasal and skull base regions; the majority of these tumors are poorly or Undifferentiated tumors manifesting overlapping features that result in diagnostic challenges. Sinonasal neuroendocrine Carcinoma (SNEC) and Sinonasal Undifferentiated Carcinoma (SNUC) are types of Sinonasal neuroendocrine tumor, together with olfactory neuroblastoma. They share overlapping clinical, radiological, and histopathological features, albeit with variability in behavior and prognosis between each other. The literature is at variance regarding the appropriate management strategy of these tumors due to their rarity and difficulty in establishing the correct diagnosis. In recent years progress has been made in the diagnostic techniques and treatment strategies implemented for these tumors. Here we provide a comprehensive review of the recent literature, focusing on the recent advances in histopathological and ancillary diagnosis, and different treatment options for SNEC and SNUC.

  • Identification of markers predictive for response to induction chemotherapy in patients with Sinonasal Undifferentiated Carcinoma.
    Oral oncology, 2019
    Co-Authors: Yoko Takahashi, Diana Bell, Jeffrey N. Myers, Ahmed S. Abdelmeguid, Dianna B. Roberts, Frederico O. Gleber-netto, Tong Xin Xie, Curtis R. Pickering, Ehab Y Hanna
    Abstract:

    Abstract Objectives Sinonasal Undifferentiated Carcinoma (SNUC) is a rare, highly aggressive cancer. Despite aggressive multimodal therapy, its prognosis remains poor. Because of its locally advanced nature and high propensity for distant metastasis, we frequently use induction chemotherapy before definitive therapy in patients with SNUC. However, about 30% of patients do not respond to induction chemotherapy, and lack of response is associated with a poor survival rate. Therefore, in this study, we performed gene expression analysis of SNUC samples to identify prognostic markers for induction chemotherapy response. Materials and methods Formalin-fixed, paraffin-embedded SNUC tumor samples from previously untreated patients harvested before induction chemotherapy were used. Gene expression was performed using an oncology gene expression panel. Results We identified 34 differentially expressed genes that distinguish the responders from the non-responders. Pathway analysis using these genes revealed alteration of multiple pathways between the two groups. Of these 34 genes, 24 distinguished between these two groups. Additionally, 16 gene pairs were associated with response to induction therapy. Conclusion We identified genes predictive of SNUC response to induction chemotherapy and pathways potentially associated with treatment outcome. This is the first report of identification of predictive biomarkers for response of SNUC to induction chemotherapy, and it may help us develop therapeutic strategies to improve the treatment outcomes of non-responders.

  • Identification of novel diagnostic markers for Sinonasal Undifferentiated Carcinoma.
    Head & neck, 2019
    Co-Authors: Yoko Takahashi, Diana Bell, Jeffrey N. Myers, Ahmed S. Abdelmeguid, Dianna B. Roberts, Frederico O. Gleber-netto, Tong Xin Xie, Curtis R. Pickering, Ehab Y Hanna
    Abstract:

    Background Sinonasal Undifferentiated Carcinoma (SNUC) is a rare, highly aggressive cancer. It is often difficult to determine whether SNUC is a distinct pathologic entity with poorly differentiated neuroendocrine features or it represents an Undifferentiated tumor of squamous lineage. Also, reliable histopathologic markers that distinguish SNUC from poorly differentiated Sinonasal squamous cell Carcinoma (SNSCC) are lacking. Therefore, identification of new diagnostic molecular markers for SNUC is needed. Methods Treatment-naive tumor specimens obtained from 15 SNUC and 6 SNSCC patients were used. Gene expression analysis was performed using an oncology panel. Results An unsupervised cluster analysis divided the patients into the one with only SNUCs and the one with mainly SNSCCs. Of 132 differentially expressed genes, 7 genes completely distinguished SNUCs from SNSCCs. SNUCs were enriched in sets of genes related to DNA repair, synthesis/replication, and cell division. Conclusions Our study identified new diagnostic markers and potential therapeutic targets for SNUC.

  • Sinonasal Undifferentiated Carcinoma.
    Current oncology reports, 2019
    Co-Authors: Ahmed S. Abdelmeguid, Diana Bell, Ehab Y Hanna
    Abstract:

    To provide a comprehensive review of the literature highlighting the recent advances in the diagnosis and management of Sinonasal Undifferentiated Carcinoma (SNUC) SNUC usually presents at advanced stage and the prognosis is usually poor with high rates of locoregional recurrence and tendency to metastasize. Special attention should be made in differentiating SNUC from other Sinonasal malignancies in order to guide the appropriate treatment accordingly. Multimodality treatment is usually recommended for treating SNUC. The use of neoadjuvant chemotherapy may be associated with improved outcome and can be used to guide the subsequent treatment selection. Despite the recent advances in chemotherapeutic agents, radiation techniques, and surgical approaches, the prognosis and survival outcomes of SNUC remain poor. The addition of induction chemotherapy to the treatment approach followed by definitive local therapy needs to be further studied as it might improve the outcome.

  • Sinonasal Undifferentiated Carcinoma
    Current Oncology Reports, 2019
    Co-Authors: Ahmed S. Abdelmeguid, Diana Bell, Ehab Y Hanna
    Abstract:

    Purpose of Review To provide a comprehensive review of the literature highlighting the recent advances in the diagnosis and management of Sinonasal Undifferentiated Carcinoma (SNUC) Recent Findings SNUC usually presents at advanced stage and the prognosis is usually poor with high rates of locoregional recurrence and tendency to metastasize. Special attention should be made in differentiating SNUC from other Sinonasal malignancies in order to guide the appropriate treatment accordingly. Multimodality treatment is usually recommended for treating SNUC. The use of neoadjuvant chemotherapy may be associated with improved outcome and can be used to guide the subsequent treatment selection. Summary Despite the recent advances in chemotherapeutic agents, radiation techniques, and surgical approaches, the prognosis and survival outcomes of SNUC remain poor. The addition of induction chemotherapy to the treatment approach followed by definitive local therapy needs to be further studied as it might improve the outcome.

Ahmad Elkhatib - One of the best experts on this subject based on the ideXlab platform.

  • role of 18 f fdg pet ct differentiating olfactory neuroblastoma from Sinonasal Undifferentiated Carcinoma
    Laryngoscope, 2017
    Co-Authors: Ahmad Elkhatib, Daniel M. Prevedello, Ricardo L. Carrau, Liuba Soldatova, Ralph Abi Hachem, Leo F. Ditzel, Raewyn Campbell, Luciano M. Prevedello, Leo Ditzel F S Filho, Raewyn G. Campbell
    Abstract:

    Objectives The purpose of this study is to demonstrate the potential contribution of positron emission tomography (PET)/computed tomography (CT) to help differentiate olfactory neuroblastoma (ONB) from Sinonasal Undifferentiated Carcinoma (SNUC). Methods Following approval by the institutional review board at the Wexner Medical Center at the Ohio State University, Columbus, Ohio, a pilot study with retrospective review of patients with biopsy-proven diagnosis of ONB s and SNUC s was conducted. Staging PET/CT scans were reviewed to document the maximum standardized uptake value (SUVmax). A statistical comparison of SUVmax was performed. Results We identified 13 patients (7 with ONBs and 6 with SNUCs) with mean age 60.2 years who had undergone staging F-18 fluorodeoxyglucose (18F-FDG) PET/CT of the primary tumor at the time of their diagnosis. Mean SUVmax was found to be five-fold higher in SNUC patients (35.63, range 10.8–77.9) than in ONB patients (7.24, range 4.6–10.7) (P ≤ 0.00169). Conclusion Maximum standardized uptake value of 18F-FDG PET/CT can be used to initially discriminate between ONB and SNUC. This finding may prove helpful to guide diagnostic and treatment planning when the histopathologic diagnosis is inconclusive. Level of Evidence 4. Laryngoscope, 2016

  • Role of (18) F-FDG PET/CT differentiating olfactory neuroblastoma from Sinonasal Undifferentiated Carcinoma.
    The Laryngoscope, 2016
    Co-Authors: Ahmad Elkhatib, Daniel M. Prevedello, Ricardo L. Carrau, Liuba Soldatova, Ralph Abi Hachem, Leo F. Ditzel, Raewyn Campbell, Luciano M. Prevedello, Leo F. S. Ditzel Filho, Raewyn G. Campbell
    Abstract:

    Objectives The purpose of this study is to demonstrate the potential contribution of positron emission tomography (PET)/computed tomography (CT) to help differentiate olfactory neuroblastoma (ONB) from Sinonasal Undifferentiated Carcinoma (SNUC). Methods Following approval by the institutional review board at the Wexner Medical Center at the Ohio State University, Columbus, Ohio, a pilot study with retrospective review of patients with biopsy-proven diagnosis of ONB s and SNUC s was conducted. Staging PET/CT scans were reviewed to document the maximum standardized uptake value (SUVmax). A statistical comparison of SUVmax was performed. Results We identified 13 patients (7 with ONBs and 6 with SNUCs) with mean age 60.2 years who had undergone staging F-18 fluorodeoxyglucose (18F-FDG) PET/CT of the primary tumor at the time of their diagnosis. Mean SUVmax was found to be five-fold higher in SNUC patients (35.63, range 10.8–77.9) than in ONB patients (7.24, range 4.6–10.7) (P ≤ 0.00169). Conclusion Maximum standardized uptake value of 18F-FDG PET/CT can be used to initially discriminate between ONB and SNUC. This finding may prove helpful to guide diagnostic and treatment planning when the histopathologic diagnosis is inconclusive. Level of Evidence 4. Laryngoscope, 2016